Dr. Abidi Pharmaceutical Laboratories (DABID) cash flow statement
Operating, investing and financing cash flows, and the closing balance
Fundamental analysis of DABID on Fundai: DABID Fundamental Analysis, Mehr 1405: Profit Forecast and Valuation
- Ticker
- DABID
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/06/31 | To 1402/06/31 | To 1401/06/31 | To 1400/06/31 |
|---|---|---|---|---|---|---|
| Cash generated from operations | -29,624,635 | 23,990,018 | 16,433,764 | 5,956,145 | -1,180,506 | 1,417,758 |
| Cash payments for income tax | -3,627,223 | -1,223,618 | -1,982,542 | -896,665 | -910,592 | -682,175 |
| Net cash inflow (outflow) from operating activities | -33,251,858 | 22,766,400 | 14,451,222 | 5,059,480 | -2,091,098 | 735,583 |
| Cash receipts from sale of property, plant and equipment | 348,016 | 138,781 | 0 | 0 | 0 | 0 |
| Cash payments for purchase of property, plant and equipment | -9,698,962 | -4,473,182 | -5,788,513 | -10,002,715 | -1,919,345 | -2,612,027 |
| Cash payments for acquisition of long-term investments | -19,404,257 | -8,160,441 | -1,731,378 | -3,184,449 | -206,416 | -15,010 |
| Cash receipts from sale of short-term investments | 720,135 | 0 | 0 | 2,830,419 | 0 | 0 |
| Cash receipts from dividends | 528,433 | 0 | 0 | 0 | 0 | 0 |
| Cash receipts from interest on other investments | 52,786 | 58,045 | 0 | 195,017 | 190,109 | 15,885 |
| Net cash inflow (outflow) from investing activities | -27,453,849 | -12,997,053 | -7,519,891 | -10,161,728 | -4,214,477 | -2,614,812 |
| Net cash inflow (outflow) before financing activities | -60,705,707 | 9,769,347 | 6,931,331 | -5,102,248 | -6,305,575 | -1,879,229 |
| Cash receipts from facilities | 188,703,290 | 82,379,747 | 51,500,436 | 34,918,077 | 31,466,255 | 19,646,000 |
| Cash payments for principal of loans | -123,176,699 | -71,976,389 | -50,486,501 | -28,092,233 | -24,517,708 | -16,666,104 |
| Cash payments for interest on loans | -27,740,814 | -9,863,661 | -6,571,662 | -2,805,226 | -2,449,528 | -1,485,220 |
| Cash receipts from issuance of participation bonds | 26,120,958 | 0 | 5,000,000 | 6,000,000 | 3,000,000 | 639,554 |
| Cash payments for dividends | -5,611,869 | -1,052,506 | -1,447,445 | -1,737,955 | -448,691 | -109,483 |
| Net cash inflow (outflow) from financing activities | 58,294,866 | -512,809 | -4,916,510 | 6,894,161 | 6,677,168 | 2,024,747 |
| Net increase (decrease) in cash | -2,410,841 | 9,256,538 | 2,014,821 | 1,791,913 | 371,593 | 145,518 |
| Cash balance at beginning of year | 5,634,817 | 2,814,653 | 752,337 | 438,618 | 215,519 | 102,776 |
| Cash balance at end of year | 3,223,976 | 12,071,191 | 2,767,158 | 2,249,168 | 579,947 | 277,500 |
Reporting periods
77 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.